Hard Evidence of Corporate Takeover at All Levels of Government in America !

WP_20140814_h099556

Hard Evidence of Corporate Takeover at All Levels of Government in America, as Well as of the United Nations


GO TO THE BOTTOM ON THE PAGE:

DUNS NUMBERS FOR EACH STATE IS
BELOW.
Hard Evidence of Corporate Takeover at All Levels of
Government in America, as Well as of the United Nations
Dunn & Bradstreet (D&B) DUNS code number are assigned to corporations in America to track their credit ratings.
Below you will find the DUNS numbers for the aggregate US government and each of its
major agencies, those of the aggregate governments of each US state along with that of its largest city,
and those of the aggregate United Nations and some of its major agencies. These corporate code
numbers can be verified by using the following link to the D&B website and typing in the required information:
http://mycredit.dnb.com/search for duns number/
In checking DUNS code numbers for governments, you will find that they have many subsidiaries and
shell corporations to lessen financial accountability.
You will find that some of them are listed as being in a geographical location
other than in their territorial authority, making their operations even more suspicious.
The City of Chicago corporation, for example, is located in Washington, DC, the State of
Montana Corporation is located in Chicago, Illinois and the State of Maine
corporation listed with seemingly sardonic humor as “State Maine Inc.” is located in New York City, New York.You will
often also see executive, legislative and judicial offices themselves listed as corporations.
Manta.com is a website for obtaining data on corporations.
If the names of any of these government
entities are entered, you will find that virtually all of them are listed as private, for profit corporations.
You will also see in the aggregate valuations of their assets that Manta.com provides is
vastly greater than what is listed in these private government corporations’ fraudulent but well publicized
budget documents that seek to justify draconian but fraudulent budget cuts and their related tax based extortion rackets.
This confirms that many hundred trillions of dollars of the people’s money listed in the semisecret
government comprehensive annual financial reports (CAFRs) as government institutional investments are
being siphoned off by the global banking cartel and those sinister forces behind it.
They are doing this via that obscure subsidiary of the private, for profit Federal Reserve System known as
the Depository Trust Clearing Center (DTCC), dba Cede Inc.
(Again, note the sardonic humor.)
This semi secret entity fraudulently confiscates these investment funds as an executor after they have been
registered by brokers, relegating investors to mere beneficiaries whose funds can then be lawfully at
least according to presently and commonly used Universal Commercial Code (UCC
based statutory law,not constitutional or common law confiscated at the will of said executor.
The implications of this are staggering: not only has this corporate subversion of government happened
in America and with the United Nations headquarter
ed here, but it has happened in almost all of the
nations of the world by means of similar corporate subversion enacted under different names.
This definitely explains why governments at all levels in almost all nations no longer protect the public interest, but only special interests
specifically, the interests of their fellow predatory for profit corporations whose
actions are now destroying this planet and all life upon it This explains why the people of the world are soon going to see sweeping constitutionally
based legal and law enforcement actions in all of the nations of the world against those who, unrepentantly abusing these ill
gotten gains, have perpetrated crimes against nature and humanity. This also explains the honest transitional governments
and financial systems that are going to be installed as the callous,
corrupt human systems of the past collapse. The new transparent governmental and financial models
now being tested in the nation of Iceland, as well as the likewise poorly publicized/contextualized mass
resignations of government, banking and corporate officials now occurring worldwide are heralds of these
imminent planetary events

WP_20140814_h099553WP_20140814_h099554

WP_20140814_h099555

====================================

 

Executive Order 13295: Revised List Of Quarantinable Communicable Diseases

Printer friendly version Adobe PDF file [64KB, 1 page]

 

NOTICE

Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this Web site was developed for the 2003 SARS epidemic. But, some guidelines are still being used. Any new SARS updates will be posted on this Web site.

NOTICE

Executive Order 13295 was amendedExternal Web Site Icon on July 31, 2014. Subsection (b) was replaced with the following:
“(b) Severe acute respiratory syndromes, which are diseases that are associated with fever and signs and symptoms of pneumonia or other respiratory illness, are capable of being transmitted from person to person, and that either are causing, or have the potential to cause, a pandemic, or, upon infection, are highly likely to cause mortality or serious morbidity if not properly controlled. This subsection does not apply to influenza.”

Office of the Press Secretary

For Immediate Release
April 4, 2003

By the authority vested in me as President by the Constitution and the laws of the United States of America, including section 361(b) of the Public Health Service Act (42 U.S.C. 264(b)), it is hereby ordered as follows:

Section 1. Based upon the recommendation of the Secretary of Health and Human Services (the “Secretary”), in consultation with the Surgeon General, and for the purpose of specifying certain communicable diseases for regulations providing for the apprehension, detention, or conditional release of individuals to prevent the introduction, transmission, or spread of suspected communicable diseases, the following communicable diseases are hereby specified pursuant to section 361(b) of the Public Health Service Act:

(a) Cholera; Diphtheria; infectious Tuberculosis; Plague; Smallpox; Yellow Fever; and Viral Hemorrhagic Fevers (Lassa, Marburg, Ebola, Crimean-Congo, South American, and others not yet isolated or named).

(b) Severe Acute Respiratory Syndrome (SARS), which is a disease associated with fever and signs and symptoms of pneumonia or other respiratory illness, is transmitted from person to person predominantly by the aerosolized or droplet route, and, if spread in the population, would have severe public health consequences.

Sec. 2. The Secretary, in the Secretary’s discretion, shall determine whether a particular condition constitutes a communicable disease of the type specified in section 1 of this order.

Sec. 3. The functions of the President under sections 362 and 364(a) of the Public Health Service Act (42 U.S.C. 265 and 267(a)) are assigned to the Secretary.

Sec. 4. This order is not intended to, and does not, create any right or benefit enforceable at law or equity by any party against the United States, its departments, agencies, entities, officers, employees or agents, or any other person.

Sec. 5. Executive Order 12452 of December 22, 1983, is hereby revoked.

George W. Bush

The White House,

April 4, 2003.

============================

Executive Order 13527 — Medical Countermeasures Following a Biological Attack

ESTABLISHING FEDERAL CAPABILITY FOR THE TIMELY PROVISION OF
MEDICAL COUNTERMEASURES FOLLOWING A BIOLOGICAL ATTACK

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered as follows:

Section 1. Policy. It is the policy of the United States to plan and prepare for the timely provision of medical countermeasures to the American people in the event of a biological attack in the United States through a rapid Federal response in coordination with State, local, territorial, and tribal governments.

This policy would seek to: (1) mitigate illness and prevent death; (2) sustain critical infrastructure; and (3) complement and supplement State, local, territorial, and tribal government medical countermeasure distribution capacity.

Sec. 2. United States Postal Service Delivery of Medical Countermeasures. (a) The U.S. Postal Service has the capacity for rapid residential delivery of medical countermeasures for self administration across all communities in the United States. The Federal Government shall pursue a national U.S. Postal Service medical countermeasures dispensing model to respond to a large-scale biological attack.

(b) The Secretaries of Health and Human Services and Homeland Security, in coordination with the U.S. Postal Service, within 180 days of the date of this order, shall establish a national U.S. Postal Service medical countermeasures dispensing model for U.S. cities to respond to a large-scale biological attack, with anthrax as the primary threat consideration.

(c) In support of the national U.S. Postal Service model, the Secretaries of Homeland Security, Health and Human Services, and Defense, and the Attorney General, in coordination with the U.S. Postal Service, and in consultation with State and local public health, emergency management, and law enforcement officials, within 180 days of the date of this order, shall develop an accompanying plan for supplementing local law enforcement personnel, as necessary and appropriate, with local Federal law enforcement, as well as other appropriate personnel, to escort U.S. Postal workers delivering medical countermeasures.

Sec. 3. Federal Rapid Response. (a) The Federal Government must develop the capacity to anticipate and immediately supplement the capabilities of affected jurisdictions to rapidly distribute medical countermeasures following a biological attack. Implementation of a Federal strategy to rapidly dispense medical countermeasures requires establishment of a Federal rapid response capability.

(b) The Secretaries of Homeland Security and Health and Human Services, in coordination with the Secretary of Defense, within 90 days of the date of this order, shall develop a concept of operations and establish requirements for a Federal rapid response to dispense medical countermeasures to an affected population following a large-scale biological attack.

Sec. 4. Continuity of Operations. (a) The Federal Government must establish mechanisms for the provision of medical countermeasures to personnel performing missionessential functions to ensure that mission-essential functions of Federal agencies continue to be performed following a biological attack.

(b) The Secretaries of Health and Human Services and Homeland Security, within 180 days of the date of this order, shall develop a plan for the provision of medical countermeasures to ensure that mission-essential functions of executive branch departments and agencies continue to be performed following a large-scale biological attack.

Sec. 5. General Provisions.

(a) Nothing in this order shall be construed to impair or otherwise affect:

(i) authority granted by law to a department or agency, or the head thereof; or
(ii) functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.

(b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations.

(c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity, by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

BARACK OBAMA

THE WHITE HOUSE,
December 30, 2009.

=====================================

FEMA Pandemic Exercise Series

PANDEMIC ACCORD: 2013-14 Pandemic Influenza Continuity Exercise Strategy 

Overview

The Federal Executive Boards in New York City and Northern New Jersey in partnership with FEMA Region II, The Department of Health and Human Services Region II, NYC Department of Health and Mental Hygiene, Securities Industry and Financial Markets Association (SIFMA) and the Clearing House Association are sponsoring a two year series of pandemic influenza continuity exercises – tabletop exercise 2013 (complete), full scale exercise 2014 –  to increase readiness for a pandemic event amongst Federal Executive Departments and Agencies, US Court, State, tribal, local jurisdictional and private sector continuity.

Pandemic influenza is a global outbreak of disease that occurs when a new influenza virus appears or “emerges” in the human population causing serious illness, as it spreads from person to person worldwide.  History teaches us that the impact of a pandemic can be far-reaching.  The 1918 “Spanish Flu” influenza killed approximately 30,000 people in NYC, 500,000 in the United States and as many as 50 -100 million worldwide.  Furthermore, it leads to widespread social disruption and economic loss.

Pandemic influenza is unique in that, unlike many other catastrophic events, it will not directly affect physical infrastructure.  While a pandemic will not damage power lines, banks, or computer networks, it will ultimately threaten all critical infrastructures by its impact on an organization’s human resources causing a loss essential personnel from the workplace for weeks or months –National Strategy for Pandemic Influenza Implementation Plan (May 2006).

Economists, epidemiologists and other experts predict that the effects of a modern-day pandemic will be seen in every industry and government agency at local, regional, national and international levels.  Typically a pandemic influenza will come in “waves” each lasting 6-8 weeks with several months between each wave.  The CDC estimates that between 35%-40% of the United States population could be affected by pandemic influenza and the economic impact could range between $71.3 and $166.5 billion (2006 estimates).

The exercise objectives are to mitigate vulnerabilities during a pandemic influenza outbreak; to identify gaps or weaknesses in pandemic planning or in organization pandemic influenza continuity plans, policies, & procedures; and encourage public and private organizations to jointly plan for, and test, their pandemic influenza plans.

============================

Rabies Vaccine Protects Nonhuman Primates Against Deadly Ebola Virus

Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, which may lead to shock, bleeding, multi-organ failure, and death. Since it first appeared in 1976 in two simultaneous outbreaks in the Sudan and Zaire (now the Democratic Republic of the Congo), Ebola virus has infected roughly 1,800 people and caused nearly 1,300 deaths. According to the World Health Organization, Ebola infection has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine.

An electron microscopic view of Ebola virus particles

An electron microscopic view of Ebola virus particles.
Credit: NIAID

Background

Increased Ebola virus outbreaks — including the 2012 outbreaks in Uganda and the Democratic Republic of the Congo — and the virus’ potential for use as a bioterrorism agent have spurred research and development to develop a safe and effective vaccine.

Although several vaccine strategies, such as those involving DNA, adenovirus, and recombinant vesicular stomatitis virus, have shown promise in protecting nonhuman primates, various factors have served to slow progress in their continued development. Recent investigations have focused on identifying the vaccine-induced immune responses that may serve as indicators of protection against Ebola infection.

Researchers from NIAID and Thomas Jefferson University, in Philadelphia, developed a vaccine based on the established rabies virus vaccine that, when tested in mice, proved safe and provided protection against both rabies and Ebola infection. As the next step to that success, the researchers tested three different types of the novel rabies/Ebola vaccine in nonhuman primates to determine their protective effect.

In their investigation, the results of which were published online May 30, 2013, the researchers tested a replication-competent rabies virus vaccine, a replication-deficient rabies virus vaccine, and a chemically inactivated rabies virus vaccine expressing Ebola glycoprotein. Fifteen rhesus macaques, divided into four groups, were immunized intramuscularly with one of the three vaccines or a control vaccine. All of the animals were followed for both rabies and Ebola-specific immune responses. After 42 days, all of the nonhuman primates were transferred to NIAID’s biosafety level-4 facility at Rocky Mountain Laboratories in Hamilton, Montana, for challenge with the Ebola virus.

Results and Significance

All three vaccines produced potent immune responses against both rabies and Ebola. In terms of protection, the live replication-competent vaccines provided 100 percent protection following challenge with the Ebola virus. The replication-deficient and inactivated vaccines afforded 50 percent protection. According to the researchers, the protection of the immunized animals against Ebola virus infection was largely dependent on the quality of the B-cell driven immune response rather than the quantity of the response. These humoral immune responses as well as high glycoprotein-specific antibodies were particularly helpful in controlling Ebola virus infection after immunization, the researchers wrote.

The results of these studies further support the concept that a successful Ebola vaccine needs to induce strong antibodies to the virus, according to the researchers. It also demonstrates that a dual-purpose vaccine to protect against rabies and Ebola virus is possible and, perhaps, more readily marketable. The research team is pursuing the inactivated rabies/Ebola vaccine for use in humans. The live vaccine is being developed for use in protecting wildlife at risk of Ebola virus infection in Africa, which could also serve to prevent transmission into the human population.

Next Steps

According to the researchers, advance testing among nonhuman primates involving higher levels of Ebola virus glycoprotein and, perhaps, an additional immunization dose could bring the protection rate to 100 percent. In addition, the research team is using the vaccine platform to develop a multivalent filovirus vaccine and other vaccine candidates against high consequence pathogens.